Quest Diagnostics announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer, effective February 26, 2026. In this role, Mr. Beauvalot is responsible for developing the company's growth strategy and leading mergers and acquisitions, strategic partnerships, and integrations. He reports to Jim Davis, chairman, CEO and president, and is a member of the company's executive leadership team.
Prior to joining Quest, Mr. Beauvalot held leadership positions in strategy and M&A with Danaher Corporation, a leading global life sciences and diagnostics innovator. Mr. Beauvalot's roles included vice president and head of business development and strategy for Danaher's biotechnology and genomics business areas. Mr. Beauvalot also served as vice president of strategy and corporate development and vice president of global business operations for Patheon, a leading pharmaceutical services company, before its acquisition by Thermo Fisher Scientific in 2017.
He was also vice president of strategy for Banner Life Sciences, a specialty pharmaceutical company. Mr. Beauvalot holds a degree in management and business administration from the Institut de Préparation à l'Administration et à la Gestion (IPAG) in Paris, France. Mr. Beauvalot succeeds Dermot Shorten, who is retiring in the second quarter of 2026 after having held the role since 2008.
During his time at Quest, Mr. Shorten oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories over the past decade.
